TISSUE REPAIR LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.245 AUD | -2.00% |
|
+6.52% | +11.36% |
| 02-29 | Tissue Repair Limited Announces Change of Company Secretary | CI |
| 02-28 | Tissue Repair Ltd Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
| Sales 2022 | 172K 112K 8.96M | Sales 2023 | 972K 635K 50.63M | Capitalization | 16.33M 10.67M 851M |
|---|---|---|---|---|---|
| Net income 2022 | -6M -3.92M -313M | Net income 2023 | -4M -2.61M -208M | EV / Sales 2022 | -60.1 x |
| Net cash position 2022 | 25.46M 16.64M 1.33B | Net cash position 2023 | 21.4M 13.99M 1.11B | EV / Sales 2023 | -5.22 x |
| P/E ratio 2022 |
-1.82
x | P/E ratio 2023 |
-3.91
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 35.68% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.00% | ||
| 1 week | +6.52% | ||
| Current month | +11.36% | ||
| 1 month | +4.26% | ||
| 6 months | -3.92% | ||
| Current year | +11.36% |
1 week
0.23
0.25
1 month
0.220.25
Current year
0.220.26
1 year
0.210.35
3 years
0.200.83
5 years
0.200.83
10 years
0.200.83
| Managers | Title | Age | Since |
|---|---|---|---|
Cameron Jones
DFI | Director of Finance/CFO | - | - |
Mark Waring
CTO | Chief Tech/Sci/R&D Officer | - | - |
Darryl Reed
COO | Chief Operating Officer | - | 31/05/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 67 | 12/08/21 | |
Tony Charara
FOU | Founder | - | 31/12/11 |
| Director/Board Member | - | 06/10/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/05/24 | 0.245 | -2.00% | 27 149 |
| 30/04/24 | 0.25 | 0.00% | 42,499 |
| 29/04/24 | 0.25 | +8.70% | 104,297 |
| 26/04/24 | 0.23 | 0.00% | 8,761 |
| 23/04/24 | 0.23 | -4.17% | 6,001 |
Delayed Quote Australian S.E., May 01, 2024 at 06:21 am
More quotes
Tissue Repair Limited is an Australia-based Phase 3 advanced biotechnology company developing second generation wound healing agents. The Company's core focus is entering Phase 3 clinical trials in chronic wounds for its lead drug candidate TR987, with a secondary focus on commercializing TR Pro+ a post procedure topical gel to accelerate healing and improve skin quality following cosmetic and medical procedures. Its TR Pro+ product provides a range of benefits that assists damaged skin to heal and maintains skin hydration for a moist healing environment to encourage normal scar formation. The Company is also focused on commercializing its propriety Glucoprime active pharmaceutical ingredient (API) to treat a variety of wounds and skin conditions. Glucoprime is a β-glucan molecule, which is designed to assist skin healing and is delivered topically in a hydrogel formulation.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +11.36% | 9.82M | |
| -0.71% | 102B | |
| +3.33% | 96.09B | |
| +2.13% | 22.28B | |
| -14.94% | 21.4B | |
| -8.79% | 18.14B | |
| -39.98% | 17.02B | |
| -13.08% | 16.09B | |
| +7.51% | 13.83B | |
| +35.80% | 11.97B |
- Stock Market
- Equities
- TRP Stock
